International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.7948651
Original Article
Sonographic Evaluation of Carotid Intima-Media Thickness (CIMT) As a Predictor of Cardiovascular Risk in Women Diagnosed With Polycystic Ovary Syndrome
 ,
 ,
 ,
 ,
 ,
 ,
 ,
Published
May 18, 2023
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age. It is associated with increased risk of cardiovascular disease (CVD). Carotid artery intima-media thickness (CIMT) is a non-invasive marker for early detection of CVD. The aim of this study was to evaluate CIMT as a predictor of CVD risk in patients with PCOS. Methods: This was a case-control study conducted on 100 women with PCOS and 100 healthy controls. Participants underwent assessment of CIMT, lipid profile, fasting blood glucose, insulin resistance, and other cardiovascular risk factors. Correlation analysis was performed between CIMT and various risk factors. Results: The mean CIMT was significantly higher in the PCOS group compared to the control group (p<0.001). The PCOS group also had lower levels of HDL cholesterol and higher levels of LDL cholesterol, homocysteine, and ferriman-gallwey score than the control group. CIMT was positively correlated with total cholesterol, HOMA-IR, and FGS, and negatively correlated with HDL cholesterol. However, no significant correlation was found between CIMT and age, BMI, fasting blood glucose, DHEAS, SHBG, total testosterone, triglycerides, HbA1c, homocysteine, FGS, blood pressure, waist-hip ratio, or FAI. Conclusion: This study suggests that CIMT can be used as a non-invasive predictor of CVD risk in patients with PCOS. Further studies with larger sample sizes are warranted to confirm these findings.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
1912 Views
253 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved